The Mumps drugs in development market research report provides comprehensive information on the therapeutics under development for Mumps, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mumps. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mumps and features dormant and discontinued products.

GlobalData tracks 12 drugs in development for Mumps by ten companies/universities/institutes. The top development phase for Mumps is preclinical with three drugs in that stage. The Mumps pipeline has nine drugs in development by companies and three by universities/ institutes. Some of the companies in the Mumps pipeline products market are: Beijing Minhai Biotechnology, University of Georgia and Daiichi Sankyo.

The key targets in the Mumps pipeline products market include 0.

The key mechanisms of action in the Mumps pipeline product include 0 with 0 drug in 0. The Mumps pipeline products include one routes of administration with the top ROA being Subcutaneous and four key molecule types in the Mumps pipeline products market including Live Attenuated Vaccine, and Vaccine.

Mumps overview

Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus that is spread from person to person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers for relief of symptoms.

For a complete picture of Mumps’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.